Identifying novel targets to extend human healthspan

Learn More

Our strategy

Systematic Medicines mission is to identify novel targets and therapeutic strategies to modulate the root causes of the ageing process. Our core differentiators from other ageing startups are:

  • Funding model allows long term strategy. We are fully funded by our parent company Leading Technology Group (LTG), allowing us to pursue the science with the best long term potential, rather than the hot topic of the day.
  • Scientific rigor. Good experimental design and statistical analysis is at the core of all our research.
  • LTGs expertise. Our sister companies bring deep expertise in clinical trials and translational research.

Recent publications

1. Owen BM, Phie J, Huynh J, Needham S, Fraser C. Evaluation of quantitative biomarkers of aging in human PBMCs. Front Aging. 2023;4:1260502.

2. Fraser C, Owen BM. Naive T-cell decline is a significant contributor to expression changes in ageing blood. Front Aging. 2024;5:1389789.

 

Contact us

Level 11, 655 Elizabeth Street
Melbourne VIC 3000
Australia

Email: info@systematicmedicine.com

© 2024 SYSTEMATIC MEDICINE

Privacy Settings
We use cookies to enhance your experience while using our website. If you are using our Services via a browser you can restrict, block or remove cookies through your web browser settings. We also use content and scripts from third parties that may use tracking technologies. You can selectively provide your consent below to allow such third party embeds. For complete information about the cookies we use, data we collect and how we process them, please check our Privacy Policy
Youtube
Consent to display content from - Youtube
Vimeo
Consent to display content from - Vimeo
Google Maps
Consent to display content from - Google